94 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number
8-K
EX-2.1
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
, severance, property, production, sales, use, duty, license, excise, franchise, employment, personal property, capital stock, social security (or similar
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social
8-K
EX-99.1
oclt2t3
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
8-K
EX-99.1
qbyt6sjl
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
8-K
EX-99.1
wns6xcgvwydyfh
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm
424B4
9ly5omt 66yk16x5g
20 Apr 23
Prospectus supplement with pricing info
6:03pm
8-K
EX-99.1
y2lxt5ky7
5 Dec 22
Other Events
7:48am
8-K
EX-99.1
e2yern9tm
14 Nov 22
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
7:33am
8-K
EX-99.1
c52lxtpf0iat
23 Aug 22
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
8:30am
8-K
EX-99.1
jbsahuud2jcdlce ve
11 Aug 22
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
4:06pm
8-K
EX-99.1
iu32apeajruh 9xmgj0h
23 May 22
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
4:01pm
S-8
EX-99.1
tid qnx72rgzj2qbjzw
18 May 22
Registration of securities for employees
4:12pm
8-K
EX-99.1
s4sp2ktz7im307e
5 May 22
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
4:04pm